In a nutshell This study aimed to investigate the long-term outcomes of nilotinib (Tasigna) versus imatinib (Gleevec) in patients with chronic-phase chronic myeloid leukemia (CP-CML). This study concluded that nilotinib provided good long-term outcomes for these patients. Some background CML results from a gene...
Read MoreType of leukemia-Chronic Myeloid Leukemia (CML) Posts on Medivizor
Long term outcomes of dasatinib as a second line treatment in patients with chronic myeloid leukemia
In a nutshell This study aimed to investigate the long-term outcomes of dasatinib treatment for patients with chronic myeloid leukemia who were resistant or intolerant to imatinib in daily clinical practice. This study concluded that dasatinib is safe and effective in these patients. Some background...
Read MoreTreatment choices and outcomes for childhood chronic myeloid leukemia
In a nutshell This study aimed to investigate treatment outcomes with transplant and tyrosine kinase inhibitors for childhood chronic myeloid leukemia. This study concluded that some tyrosine kinase inhibitors provide better outcomes for these patients. Some background Chronic myeloid leukemia (CML) is a rare disease in childhood....
Read MoreEvaluating antithymocyte globulin in preventing graft-versus-host-disease after matched sibling donor transplantation
In a nutshell This study aimed to investigate the role of antithymocyte globulin in preventing graft-versus-host disease after matched sibling donor transplantation. This study concluded that this treatment can reduce the occurrence of graft-versus-host-disease in these patients. Some background One...
Read MoreImpact of graft cryopreservation on allogeneic hematopoietic stem cell transplant outcomes using post-transplant cyclophosphamide
In a nutshell This study aimed to compare outcomes of allogeneic hematopoietic stem cell transplant (alloHSCT) using cryopreserved (frozen) and fresh grafts in patients with blood cancers who received post-transplant cyclophosphamide (Cytoxan). This study concluded that cryopreservation (CP) does not affect the outcomes of HSCT in these patients....
Read MoreManaging patients with chronic myeloid leukemia who fail responding to second generation tyrosine kinase inhibitors
In a nutshell The report recommends how to manage patients with chronic-phase chronic myeloid leukemia (CP-CML) who failed to respond to 2nd generation tyrosine kinase inhibitors (TKIs). The authors suggested to consider patient-specific factors and personalize treatment for such patients. Some background TKIs deactivate cancerous enzymes which cause...
Read MoreSwitching from frontline second-generation tyrosine kinase inhibitor treatment in chronic myeloid leukemia
In a nutshell This study aimed to investigate second treatments in patients with chronic myeloid leukemia (CML) who had been initially treated with second-generation tyrosine kinase inhibitors (TKI). This study concluded that switching from second-generation TKIs in these patients was relatively uncommon. Some background...
Read MoreKidney function in patients with chronic myeloid leukemia after stopping tyrosine kinase inhibitors
In a nutshell This study aimed to investigate kidney function in patients with chronic-phase (CP) chronic myeloid leukemia (CML) before and after tyrosine kinase inhibitor (TKI) treatment. This study concluded that long-term TKI treatment leads to kidney side effects in these patients that may be irreversible after stopping...
Read MoreDo stem cell transplants improve patients’ long-term survival?
In a nutshell This study examined the long-term survival of patients who received stem cell transplants (SCT) and compared them to the general population. The authors found that patients who received SCTs had almost the same chance of survival as the general population and identified factors that alter this chance. Some background Treatments such as...
Read MoreDo stem cell transplants improve patients’ long-term survival?
In a nutshell This study examined the long-term survival of patients who received stem cell transplants (SCT) and compared them to the general population. The authors found that patients who received SCTs had almost the same chance of survival as the general population and identified factors that alter this chance. Some background Treatments such as...
Read MoreThe effect of stomach acid suppressants on the safety and effectiveness of dasatinib in patients with chronic myeloid leukemia
In a nutshell This study aimed to investigate the influence of stomach acid suppressants on dasatinib treatment in patients with chronic-phase chronic myeloid leukemia. This study concluded that these drugs did not influence dasatinib treatment in this patient group. Some background...
Read MoreThe effects of hydroxychloroquine and imatinib on treatment outcomes in patients with chronic myeloid leukemia
In a nutshell The study evaluated the combined effects of imatinib (IM; Gleevec) and hydroxychloroquine (HCQ; Plaquenil) in patients with chronic-phase chronic myeloid leukemia (CP-CML) and residual leukemic stem cells. The authors found that this combination safely and moderately improved treatment outcomes in such patients compared to IM alone. Some...
Read More